GSK's Blood Cancer Drug Fails FDA Panel, Shares Plummet 6% in Volatile Session

Summary
• GSK shares trade at $35.95, down 6.09% from previous close of $38.28
• FDA panel recommends against Blenrep for blood cancer treatment, citing safety concerns
• Options chain shows heavy activity at $34-36.5 strike prices
• Technical indicators suggest short-term bearish momentum with long-term range-bound outlook

GSK's stock is in freefall after the FDA's advisory panel rejected its blood cancer drug Blenrep, sending shares down nearly 6% to $35.95. The drug's regulatory setback has triggered heavy options trading and amplified volatility. With the stock trading near its 52-week low of $31.72, investors are recalibrating positions as the FDA prepares its final decision next week.

FDA Panel Rejects Blenrep for Blood Cancer Treatment
GSK's shares have collapsed following a decisive FDA advisory panel vote against its blood cancer drug Blenrep. The panel rejected both combination therapies (Blenrep with Velcade and Blenrep with Pomalyst) in a 5-3 and 7-1 vote respectively, citing safety concerns particularly around ocular toxicity. This regulatory setback follows the drug's 2022 withdrawal from the US market after it failed to show superiority over existing treatments. The panel's concerns include the drug's dosing regimen and limited US patient representation in clinical trials. With the FDA expected to make its final decision by July 23, the market is pricing in significant uncertainty for GSK's oncology pipeline.

Pharmaceutical Sector Mixed Amid Regulatory Scrutiny
While GSK's shares have been hammered, the broader pharmaceutical sector shows mixed performance. Johnson & Johnson (JNJ) is down 0.66%, reflecting sector-wide regulatory concerns. The FDA's increased scrutiny of drug safety profiles is impacting investor sentiment across the sector, particularly for oncology-focused companies. However, GSK's 6% decline is more pronounced given the direct impact on its key blood cancer treatment candidate.

Options and ETF Strategies for GSK's Volatile Outlook
• 200-day average: 37.08 (below current price)
• RSI: 50.0 (neutral)
• MACD: -0.28 (bearish)
• Bollinger Bands: 37.59-39.49 (price at lower band)
• Volume: 11.5 million (elevated)

Given the technical indicators and options chain activity, conservative investors might consider using SPXL or UPRO for market exposure while monitoring key support levels. The stock is currently trading near its 200D support range of 33.95-34.16, with the 52-week low at 31.72 providing a critical watchpoint. The Direxion Daily S&P 500 Bull 3X Shares (SPXL) at $181.04 with a 1.79% gain could be useful for leveraged exposure if the broader market recovers.

Two standout options from the chain include:
• GSK20250725P36.5 (Put option):
- Strike: 36.5
- Expiration: 2025-07-25
- IV: 28.05% (moderate)
- Delta: -0.607 (high sensitivity)
- Theta: -0.022 (moderate time decay)
- Gamma: 0.242 (high sensitivity to price movement)
- Turnover: 16,069
- LVR: 40.03%
This put option stands out due to its high delta and gamma, making it responsive to further price declines. With a 5% downside scenario to $34.15, the put payoff would be $2.35 per contract.

• GSK20250725P36 (Put option):
- Strike: 36
- Expiration: 2025-07-25
- IV: 31.67% (moderate)
- Delta: -0.483 (moderate sensitivity)
- Theta: -0.030 (high time decay)
- Gamma: 0.222 (high sensitivity to price movement)
- Turnover: 6,771
- LVR: 51.46%
This option offers a balance between sensitivity and liquidity, with a 5% downside scenario to $34.15 yielding a put payoff of $1.85 per contract. Its moderate delta makes it suitable for investors expecting continued downward pressure but not an immediate freefall.

If the stock breaks below $34.50, GSK20250725P36.5 offers strong short-side potential.

Backtest GSK Stock Performance
The backtest of GSK's performance after a -6% intraday plunge shows mixed results. While the stock experienced a slight decline over the short term, it tended to recover and even surpass its previous levels in the medium to long term. The 3-Day win rate was 47.59%, the 10-Day win rate was 49.66%, and the 30-Day win rate was 51.55%, indicating a higher probability of positive returns in the short to medium term. The maximum return during the backtest period was 0.11%, which occurred on day 45, suggesting that while the stock might not always immediately recover from such a significant drop, it often rebounds in the following days.

GSK Faces Regulatory Crossroads - Watch for $31.72 Breakdown
The FDA's upcoming decision on Blenrep will be pivotal for GSK's near-term prospects. With the stock already trading near its 52-week low and technical indicators pointing to continued weakness, investors should monitor the $34.50 support level. If this fails, the next critical support is at the 52-week low of $31.72. Meanwhile, sector leader Johnson & Johnson (JNJ) is down 0.66%, showing the broader regulatory concerns affecting the sector. For aggressive investors, the GSK20250725P36.5 put option offers compelling short-side exposure given its high sensitivity to price movements. Conservative investors should wait for a clearer regulatory outcome before committing to long positions.